Billioti de Gage S, Collin C, Le-Tri T, Pariente A, Bégaud B, Verdoux H, Dray-Spira R, Zureik M. Antidepressants and Hepatotoxicity: a Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018;32:673–84.

Article  PubMed  PubMed Central  Google Scholar 

Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014;171:404–15.

Article  PubMed  Google Scholar 

Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 1999;29:1347–51.

Article  CAS  PubMed  Google Scholar 

Carvajal García-Pando A, García del Pozo J, Sánchez AS, Velasco MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 2002;63:135–7.

Article  PubMed  Google Scholar 

Morgan DH. Jaundice associated with amitriptyline. Br J Psychiatry. 1969;115:105–6.

Article  CAS  PubMed  Google Scholar 

Larrey D, Pessayre D, Duhamel G, Casier A, Degott C, Feldmann G, Erlinger S, Benhamou JP. Prolonged cholestasis after ajmaline-induced acute hepatitis. J Hepatol. 1986;2:81–7.

Article  CAS  PubMed  Google Scholar 

Larrey D, Rueff B, Pessayre D, Danan G, Algard M, Geneve J, Benhamou JP. Cross hepatotoxicity between tricyclic antidepressants. Gut. 1986;27:726–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masubuchi Y, Konishi M, Horie T. Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes. Arch Toxicol. 1999;73:147–51.

Article  CAS  PubMed  Google Scholar 

Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489–99.

Article  CAS  PubMed  Google Scholar 

DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007;41:1201–11.

Article  CAS  PubMed  Google Scholar 

Yasuhara H, Dujovne CA, Ueda I, Arakawa K. Hepatotoxicity and surface activity of tricyclic antidepressants in vitro. Toxicol Appl Pharmacol. 1979;47:47–54.

Article  CAS  PubMed  Google Scholar 

Pedersen AM, Enevoldsen HK. Nortriptyline-induced hepatic failure. Ther Drug Monit. 1996;18:100–2.

Article  CAS  PubMed  Google Scholar 

Berkelhammer C, Kher N, Berry C, Largosa A. Nortriptyline-induced fulminant hepatic failure. J Clin Gastroenterol. 1995;20:54–6.

Article  CAS  PubMed  Google Scholar 

Hughes MM, O’Neill LAJ. Metabolic regulation of NLRP3. Immunol Rev. 2018;281:88–98.

Article  CAS  PubMed  Google Scholar 

Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148–59.

Article  CAS  PubMed  Google Scholar 

Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019;20:3328.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526:666–71.

Article  CAS  PubMed  Google Scholar 

Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity. 2009;30:566–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gross O, Poeck H, Bscheider M, Dostert C, Hannesschläger N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature. 2009;459:433–6.

Article  CAS  PubMed  Google Scholar 

Ahn M, Anderson DE, Zhang Q, Tan CW, Lim BL, Luko K, Wen M, Chia WN, Mani S, Wang LC, et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat Microbiol. 2019;4:789–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39:277–86.

Article  PubMed  PubMed Central  Google Scholar 

Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 2019;5:69.

Article  PubMed  Google Scholar 

Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Circ Res. 2018;122:1722–40.

Article  CAS  PubMed  Google Scholar 

Ferreira NS, Bruder-Nascimento T, Pereira CA, Zanotto CZ, Prado DS, Silva JF, Rassi DM, Foss-Freitas MC, Alves-Filho JC, Carlos D, Tostes RC. NLRP3 Inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus. Cells. 2019;8:1595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou J, Wang SP, Wang YT, Wan JB. Regulation of the NLRP3 inflammasome with natural products against chemical-induced liver injury. Pharmacol Res. 2021;164:105388.

Article  CAS  PubMed  Google Scholar 

Zhang X, Luan J, Chen W, Fan J, Nan Y, Wang Y, Liang Y, Meng G, Ju D. Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis. Nanoscale. 2018;10:9141–52.

Article  CAS  PubMed  Google Scholar 

Wang Z, Xu G, Gao Y, Zhan X, Qin N, Fu S, Li R, Niu M, Wang J, Liu Y, et al. Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome. Acta Pharm Sin B. 2019;9:734–44.

Article  PubMed  PubMed Central  Google Scholar 

Su Q, Kuang W, Hao W, Liang J, Wu L, Tang C, Wang Y, Liu T. Antituberculosis Drugs (Rifampicin and Isoniazid) Induce Liver Injury by Regulating NLRP3 Inflammasomes. Mediators Inflamm. 2021;2021:8086253.

Article  PubMed  PubMed Central  Google Scholar 

Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf. 2003;2:249–62.

Article  CAS  PubMed  Google Scholar 

O’Brien M, Moehring D, Muñoz-Planillo R, Núñez G, Callaway J, Ting J, Scurria M, Ugo T, Bernad L, Cali J, Lazar D. A bioluminescent caspase-1 activity assay rapidly monitors inflammasome activation in cells. J Immunol Methods. 2017;447:1–13.

Article  CAS  PubMed  Google Scholar 

Shi W, Xu G, Zhan X, Gao Y, Wang Z, Fu S, Qin N, Hou X, Ai Y, Wang C, et al. Carnosol inhibits inflammasome activation by directly targeting HSP90 to treat inflammasome-mediated diseases. Cell Death Dis. 2020;11:252.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Xu G, Wang H, Zhan X, Gao Y, Chen N, Li R, Song X, Guo Y, Yang R, et al. Icariside II, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation. Acta Pharm Sin B. 2020;10:1619–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu H, Zhan X, Xu G, Wang Z, Li R, Wang Y, Qin Q, Shi W, Hou X, Yang R, et al. Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases. Pharmacol Res. 2021;164:105384.

Article  CAS  PubMed  Google Scholar 

Xu G, Fu S, Zhan X, Wang Z, Zhang P, Shi W, Qin N, Chen Y, Wang C, Niu M, et al. Echinatin effectively protects against NLRP3 inflammasome-driven diseases by targeting HSP90. JCI Insight. 2021;6.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Rong H, Zhang FX, Wu K, Mu L, Meng J, Xiao B, Zamponi GW, Shi Y. A Membrane Potential- and Calpain-Dependent Reversal of Caspase-1 Inhibition Regulates Canonical NLRP3 Inflammasome. Cell Rep. 2018;24:2356-2369.e2355.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang B, Yin Q. AIM2 inflammasome activation and regulation: A structural perspective. J Struct Biol. 2017;200:279–82.